Earnings

Gossamer Bio Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $9.238M Beat $5.193M Estimate

Aug 13, 2026 · 04:18 PM ET· updated 1h ago

Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 52.94 percent increase over losses of $(0.17) per share from the

Why It Matters

Gossamer Bio lost less money per share than people thought it would, and made more sales than expected. When a company loses less money and grows sales faster, it shows the business is moving in a better direction.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

GOSS0.17

-0.01 (-3.15%)

MMM183.18

-0.60 (-0.33%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.